<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="30621">Arsenic trioxide</z:chebi> has been used successfully for the treatment of refractory <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> and has shown promise in the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), although it is not a labeled indication </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="2" ids="26536">Retinoic acid</z:chebi> syndrome is manifested by <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:hpo ids='HP_0002094'>dyspnea</z:hpo>, peripheral <z:hpo ids='HP_0000969'>edema</z:hpo>, <z:hpo ids='HP_0002113'>pulmonary infiltrates</z:hpo>, and pleural and/or <z:hpo ids='HP_0001698'>pericardial effusions</z:hpo> and is typically seen in conjunction with <z:hpo ids='HP_0000001'>all</z:hpo>- trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> therapy of <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of <z:hpo ids='HP_0011009'>acute</z:hpo> lung injury and a <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> syndrome-like illness in a patient who received <z:chebi fb="107" ids="27563">arsenic</z:chebi> for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>To our knowledge, this is the first such report, and clinicians should be aware of this potentially life-threatening complication of <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi> treatment in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>